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Abstract
The incidence of hepatocellular carcinoma (HCC) shows marked variation worldwide but the magnitude of this tumor is
reflected by the occurrence of at least 1 million new cases annually and the uniformly dismal outlook with median survivals of
525 months after resection and 56 months with symptomatic treatment. The strikingly uneven distribution of this tumor
parallels the prevalence of hepatitis B infection with rising incidence in western countries attributed to hepatitis C infection.
Chronic hepatitis and cirrhosis constitute the major preneoplastic conditions in the majority of HCCs and may be related to
other etiologic agents such as environmental chemical carcinogens including nitrites, hydrocarbons, solvents, organochlorine
pesticides, and the chemicals in processed foods, cleaning agents, cosmetics and pharmaceuticals, as well as plant toxins such
as aflatoxins produced by fungi that cause spoilage of grain and food in the tropics. Genetic diseases such as genetic hema-
tochromatosis, Wilson’s disease, a-1-antitrypsin deficiency, and the inborn errors of metabolism including hereditary tyro-
sinemia and hepatic porphyria, are known to be associated with HCC. Numerous genetic alterations and the modulation of
DNA methylation are recognized in HCC and it is likely that these genetic and epigenetic changes combine with factors
involved in chronic hepatocyte destruction and regeneration to result in neoplastic growth and multiple molecular pathways
may be involved in the production of subsets of hepatocellular tumors.
Key words: Hepatocellular carcinoma, pathogenesis, epidemiology, hepatitis, alcohol, cirrhosis, risk factors, carcinogens
Introduction
Hepatocellular carcinoma (HCC) is one of the most
common internal malignancies worldwide. In some
countries of high incidence, HCC is the leading form
of cancer and overall it rates as the seventh most
common malignancy in males and the ninth in
females [1–4].
Cancer statistics from many of the countries with
a high incidence of HCC are incomplete; as such
much of the data available may represent under-
estimates [5]. At least 1 million new cases of HCC
occur annually and mortality from the disease remains
high despite treatment [2–4], with recent results
showing 1-year, 3-year, and 5-year survival rates of
66.1%, 39.7%, and 32.5% respectively, overall and
93.5%, 70.1% and 59.1%, respectively, for early stage
patients [6]. Even in countries where the incidence is
low, median survival time after resection is 24.8
months compared with 5.8 months in symptomatically
treated patients [7].
Geographic distribution
The geographic distribution of HCC worldwide is strik-
ingly uneven (Figure 1). South-east Asian countries
(Taiwan, Korea, Thailand, Hong Kong, Singapore,
Malaysia, southern China) and tropical Africa show
the highest incidence, in the region of 10–20 per
100 000 population. The prevalence rates vary again
among these countries, with an incidence of 150 per
100 000 in Taiwan [2] and 28 per 100 000 population
in Singapore [8]. Similarly high incidence rates are
suspected in Cambodia, Vietnam, and Burma but
accurate documentation is lacking. The lowest rates of
1–3 per 100 000 population for HCC are found in
western countries, Australia, South America, and India
[9], with intermediate rates in Japan, the Middle East,
and Mediterranean countries [2–4,10,11].
In general, the incidence of HCC in migrant popu-
lations slowly equates to that of the local population
with successive generations. Indians who have settled
in Hong Kong and Singapore have acquired incidence
rates close to those of the rest of the population and
about double that of their home country; whereas the
incidence among Japanese and Korean migrants in
California and Hawaii has slowly decreased. The ex-
ceptions appear to be Chinese populations, who seem
to be at high risk regardless of location whether it be
Singapore, Shanghai, Hong Kong or elsewhere, and
Whites, who retain a low incidence even when living in
areas of high prevalence such as South-east Asia or
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Africa. This maintenance of risk has been attributed to
the continuance of the lifestyle and environment of
their home countries and parallels the hepatitis B virus
(HBV) carrier rates in these populations [2,4,11,12].
This remarkable geographical distribution has
prompted investigation into location-specific etiologi-
cal factors. It is unlikely that HCC results from a single
causative agent. As with other carcinomas, a multi-step
mechanism involving complex interactions between
multiple etiological factors is more probable. Race and
genetic factors have been found to be of no etiological
significance, rather, environmental agents are closely
related, in particular, the prevalence of chronic HBV
infection. Hepatitis C virus (HCV) infection is also
emerging as a major etiological factor, with increasing
rates of HCV infection thought to partly underlie the
increasing incidence of HCC in the western world [13].
The majority of HCCs arise in the setting of chronic
hepatitis and cirrhosis. Carcinogenesis of hepatocytes
represents a linear and progressive process in which
successively more aberrant monoclonal populations of
liver cells evolve. Regenerative hepatocytes in focal
lesions in the inflamed liver give rise to hyperplastic
nodules that progress to dysplastic nodules that are
thought to be the direct precursor of HCC. The
neoplastic transformation often results from the accu-
mulation of genetic changes during the repetitive
cellular proliferation that occurs in the damaged liver.
Risk factors
Lesser variations in the incidence of HCC have been
observed in racially homogeneous countries such as
Greece, Spain, and Italy. Such differences have been
explained by differences in HBV carriage, alcohol con-
sumption and smoking, or variations in exposure to
hepatotoxins. Switzerland, for example, a highly de-
veloped and industrialized country, has a higher than
average rate of HCC compared with other European
nations, raising the possibility of additional risks such
as exposure to hepatotoxic chemicals. In an astounding
survey of 840 million people in China during 1972–
1977, it was found that the main endemic areas for
HCC were along the south-east coast, particularly the
deltas, valleys, and islands. In these areas the standard-
ized mortality rate from HCC was 460 per 100 000
people per year compared with56 per 100 000 people
in low-incidence areas of the country [14]. In
Mozambique, a ninefold difference between the coastal
and inland region has been reported. Movement from a
rural to an urban environment has also been associated
with increased risk in countries like Norway and
Poland, whereas the reverse seems to be true for South
Africa [2–4]. Differences in levels of exposure to en-
vironmental hepatotoxins and improvements in living
standards are thought to be responsible for these
differences.
In China, high mortality rates from HCC have been
reported in coastal and riverside areas with stagnant
and polluted water supplies. However, improved living
standards can produce paradoxical effects. While they
may reduce the incidence of HCC in some commu-
nities, studies on time trends show a steady but indis-
putable rise in liver cancer rates. In Japan, the rate of
HCC has risen from 1.91% among 19 357 autopsies in
1958–1959 to 7.66% in 1986–1987 [5]. A similar rise
was observed in Los Angeles where the rate rose from
0.15% in 1918–1953 to 1.48% in 1964–1983 [15].
There seems to be a general increase in incidence of
liver cancer throughout the world with reported in-
creases among males and females in 24 and 26 of 37
countries, respectively, whose cancer registries were
examined [16]. Florence, Italy, reported an eightfold
Figure 1. Incidence of hepatocellular carcinoma worldwide.
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increase, Shanghai a twofold increase between 1959
and 1976 and Mexico a twofold increase over a 25-year
period [17]. It is unlikely that HCC is due to a single
causative agent; more likely, as with other carcinomas,
this tumor is the result of a complex interaction be-
tween multiple etiological factors and through a multi-
step mechanism. The risk factors for HCC may be
divided into genetic, and environmental and biological
factors, the more common of these are discussed
below.
Age and gender
HCC may occur from as early as 2 years of age in areas
of high incidence [18]. In general, the incidence
increases with age in all populations and shows a slight
decrease in the elderly. The age peak in a given region
tends to be inversely related to the frequency of the
tumour, i.e. the age peak is in younger patients in areas
of high incidence, and in elderly patients in areas of low
incidence. In Mozambique, where 50% of patients
with HCC are 530 years old, the incidence of the
tumor among males aged 25–34 years is 4500-fold
that of the same age group in low prevalence western
countries. This compares with only a 15-fold difference
between the elderly of both populations. Recent in-
creases in incidence in countries such as the USA have
been accompanied by a shift to a younger average
patient age [13].
HCC shows a strong male predilection, being four
and eight times more common in males in low and high
prevalence regions, respectively. While this finding
may be partly attributed to the cumulative result of
other associated factors such as the higher incidence of
cirrhosis in males, and higher levels of smoking and
alcohol intake, findings in experimental animals sug-
gest that sex hormones and/or hormone receptors may
play a role. Orchidectomy reduces the carcinogenic
effects of chemicals in male rats to the level found in
females. Implantation of stilbesterol or estradiol pellets
produces a similar but less marked effect [19,20]. Most
liver cancers show elevation of androgen receptors
[21,22], although the results of treatments targeting
hormone action and receptors have produced variable
or disappointing results [23,24]. The rate of DNA
synthesis in cirrhotic livers, a factor related to the risk
of carcinoma in such livers, is higher in men than in
women [25]. Liver adenomas associated with andro-
gen or anabolic steroids may regress with withdrawal
of the drug [26], a phenomenon also seen in tumors
induced by oral contraceptive steroids. Sex steroids
most likely act in combination with other factors as
promoters of abnormal growth.
HCC occurs in adolescence and childhood and has
been reported in children as young as 2 years of age in
Hong Kong [18]. This is not unexpected in high inci-
dence populations where the tumor is associated with
HBV infection contracted early in life [27]. Congenital
abnormalities and inborn errors of metabolism may
account for some cases, especially in western countries
[28]. Other tumors including hepatoblastoma and
fibrolamellar carcinoma have a predilection for the
young [29].
Genetic and congenital abnormalities
While a genetic susceptibility to cirrhosis and liver
cancer has been demonstrated in inbred strains of
mice, the same has not been established in man.
Familial clustering of HCC has been described in
Chinese and Alaskan natives [30,31] and cases of
liver cancer have been recorded in children of several
families for up to three generations [32,33], but these
have invariably been associated with chronic HBV
infection, as shown in the majority of cases. Analysis
of major histocompatibility complex antigens among
patients and controls in both South Africa and China
has not revealed a link with HBV infection or liver
cancer.
Rarely, liver cancer occurs in association with con-
ditions that have a genetic, congenital or metabolic
origin. HCC has been rarely documented in familial
polyposis coli [34], ataxia telangiectasia [35], familial
cholestatic cirrhosis, congenital hepatic fibrosis,
neurofibromatosis, situs inversus and the fetal alcohol
syndrome [29,36].
Among the inborn errors of metabolism, the chronic
form of hereditary tyrosinemia carries the highest risk
of liver malignancy, with one report describing liver
cancer in 16 of 43 patients [37]. Such patients showed
a rapid progression from micro- to macro-nodular
cirrhosis within a period of a few months, and then to
dysplasia and eventually HCC. To avert the latter
complication, hepatectomy and liver transplantation
before 2 years of age is now the recommended treat-
ment in this condition [38]. Type I glycogen storage
disease may be associated with adenomas but carci-
noma has rarely been reported. Hepatic porphyria
of both intermittent and cutanea tarda types have a
61-fold increased risk for HCC [39].
In one study of genetic hemochromatosis, 22% of
patients died with HCC, representing a 219-fold in-
crease over the general population [40]. Males were
commonly affected with cirrhosis and its attendant
risk of liver cancer. Iron has been suggested to have
carcinogenic properties through the production of free
radicals but this has not been substantiated. Wilson’s
disease, another autosomal recessive disorder, also
affects males more frequently and produces cirrhosis
through the accumulation of copper in hepatocytes.
A few cases of HCC have been reported in this disorder
but always accompanied by cirrhosis. Rarely, HCC
has complicated biliary cirrhosis, another condition in
which excess of copper accumulates in the liver.
Alpha-1-antitrypsin (a1AT) deficiency is associated
with jaundice and cirrhosis in early childhood, and
with pulmonary emphysema and cirrhosis in adult
life. The enzyme is synthesized in the liver and released
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into the blood. It is an inhibitor of serine proteinases,
which include trypsin, chymotrypsin and leukocyte
elastase. In a1AT deficiency, the enzyme continues to
be produced in the liver but is not secreted, accumu-
lating as visible globules in the hepatocytes. Up to 75
allelic variants of the Pi (protease inhibitor) genes
control this enzyme. PiZ is the variant associated with
low levels of serum a1AT and occurs as a homozygous
but more commonly as a heterozygous form. The
mechanisms behind the occurrence of a1AT deficiency
and HCC are still not known. a1AT globules can also
be seen in the tumor cells of both adenomas and
carcinomas of patients who do not have the PiZ gene
and who show no evidence of a1AT deficiency,
suggesting that the failure to release the enzyme may
have a promoting effect in carcinogenesis by allowing
local proteases to destroy contact inhibition that
otherwise occurs between transformed liver cells [41].
However, it is likely that other factors may also be
operative, as the association with HCC appears to
be statistically significant only for males.
Membranous obstruction of the hepatic portion of
the inferior vena cava, a type of Budd-Chiari syn-
drome, has been associated with HCC. This condition
is uncommon in the West and is seen in Japan, India
and among the black population of South Africa. The
lesion may be congenital, such as due to malformation
of the Eustachian valve, or acquired due to mechanical
injury, infection or thrombosis. In Japan, 29 of 71 cases
(41%) developed HCC, and in South Africa 20% of all
cases with HCC showed the lesion at autopsy and
47.5% of patients with radiologically demonstrated
caval obstructions developed HCC [42]. In this con-
dition passive congestion may act as a stimulus to
hepatocytes’ regeneration, although the true mecha-
nism leading to carcinoma is not known.
Cirrhosis
Cirrhosis is the most common association of HCC,
being the underlying disease in 80–90% of patients
with primary liver cancer in most countries. Non-
alcoholic post-hepatitic cirrhosis is the most common
association, but any condition that causes cirrhosis
may potentially lead to HCC, including conditions
such as inborn errors of metabolism, hereditary hemo-
chromatosis, a1AT deficiency, and Wilson’s disease
[37,40,43–45].
In a rare strain of rat in which severe hepatic necrosis
occurs spontaneously, survivors invariably develop
liver cancer after a period of chronic liver disease.
Almost any form of chronic liver disease that leads to
cirrhosis may be complicated by HCC, and cirrhosis,
whatever the cause, is a precancerous condition.
It has been shown that cirrhotic livers with large
nodules and thin intervening stroma are more com-
monly associated with HCC than livers with small
nodules and thick stroma [46]. Larger nodules are
thought to have greater regenerative activities, with
increased DNA synthesis in hepatocytes, more re-
arrangements of DNA sequences and hence greater
vulnerability to mutagenesis following exposure to
another co-factor. In patients with alcoholic cirrhosis, a
higher incidence of carcinoma was noted among those
who had abstained and whose micronodular cirrhosis
had turned macronodular, perhaps similarly linked to
the surge of regenerative activity that transforms small
nodules to large ones. Clinically, patients with alco-
holic cirrhosis seldom develop carcinoma while they
are still imbibing.
Cirrhosis is clearly not a prerequisite for HCC and
the latter is not an inevitable consequence. The two
conditions share a common cause, with some causes of
cirrhosis, such as chronic HBV infection, being associ-
ated with a higher risk of HCC than others, such as
alcohol.
Hepatitis B virus (HBV)
An etiological association between HBV and HCC has
been clearly established, although the relationship is
complex and involves other etiologic factors. Eighty
per cent of cases of HCC worldwide are estimated to be
etiologically associated with HBV infection [47] and
the incidence of HCC parallels carrier rates of HBV
infection. Improved control of HBV infection from
universal vaccination has resulted in a recent decline in
HCC in countries such as Taiwan and China [48,49].
Chronic infection with HBV imparts a 200-fold
increased risk of developing HCC. Acquisition of HBV
infection at birth or in early childhood is associated
with a greatest risk of becoming a carrier and subse-
quently developing HCC. This is attributed to the
immaturity of the immune system in this age group.
The risk falls with increasing age, with about 40% if
infected in childhood and 10% risk of carrier state
if infected as an adult [50,51]. Familial clustering of
HCC is commonly due to HBV-related disease as a
result of vertical transmission of the virus.
Carcinogenesis is thought to result from the chronic
hepatitis and cirrhosis caused by HBV, as well as from
viral integration. While HBV antigens can readily be de-
monstrated by immunostaining in the non-tumorous
hepatocytes of carriers and patients with cirrhosis and
HCC, they are less commonly found in the tumor cells.
HBV cannot be visualized in tumor cells in a replicative
form, but it can be demonstrated once integrated, by
molecular techniques. Integration of HBV DNA into
the host genome always precedes development of
HCC, although the site of integration is random
[52,53]. The precise effects of integration are yet to
be determined. It may result in transactivation of
proto-oncogenes, activation of growth factors, and
inactivation of tumor suppressor genes leading to
abnormal cell growth. The HBx gene encoded by HBV
may also contribute to the development of HCC
through a variety of effects on multiple systems
including cyclin A, protein kinases, and DNA repair.
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When HBV DNA was used as a genetic marker,
identical patterns of integration were found in multi-
focal hepatomas, and in primary tumors and their
metastases, indicating an origin from a single clone
of cells in which HBV integration had occurred before
malignant transformation [52,53].
Hepatitis C virus (HCV)
Hepatitis C virus is now emerging as the leading cause
of HCC in western countries. HCC rates in the United
States have increased by 70% over the last two decades,
with similar trends reported in Canada and Western
Europe [47]. While some of the documented increase
may be artefactual and a result of greater availability
of specialist medical services and hence increased
reporting of cases [54], at least half of this increase
in the USA has resulted from HCV-related cases.
Chronic infection by HCV is a leading risk factor in
non-Asians [55,56]. The HCV carrier rate among
Japanese blood donors is 1.2% and may be lower in
western countries. Antibodies to HCV have been
found in as high as 76% of patients with HCC in Japan,
Italy, and Spain [4].
HCV causes chronic liver disease, with eventual
development of cirrhosis and HCC. Unlike HBV,
HCV is a single-stranded RNA virus that does not
integrate into the host genome. There is currently no
evidence that HCV is of itself oncogenic; however,
HCC may rarely develop in non-cirrhotic HCV-
infected individuals, so a direct oncogenic effect cannot
be excluded.
Interestingly, there are suggestions that the presence
of HBV gene in patients with chronic HCV-associated
liver injury appears to promote hepatocarcinogenesis
[57,58], but this requires further confirmation. Human
immunodeficiency virus (HIV) co-infection results in
greater likelihood of chronicity and enhanced viral
replication in both HBV and HCV infections. HIV co-
infection hastens HCV-related liver disease with faster
progression to cirrhosis, end-stage liver disease and the
occurrence of HCC. In contrast, current evidence
suggests that HIV infection may have a negative impact
on HBV-related liver disease progression, although the
mechanisms for this are unclear [59].
Other hepatitis viruses
Other hepatitis viruses have an uncertain role in
hepatocarcinogenesis. There is an obligatory symbiosis
between hepatitis D virus (HDV) and HBV, making
evaluation of its role in hepatocarcinogenesis difficult.
However, there is evidence to indicate that HDV
infection places additional burden on the already
damaged liver, thus contributing to the risk of carci-
noma. Hepatitis A and hepatitis E infections do not
lead to chronic liver disease and have no carcinogenic
role.
Plant carcinogens
Large doses of aflatoxins produced by the fungi
Aspergillus flavis and A. parasitans are well recognized
to cause severe hepatic injury. These fungi grow readily
on grains, peanuts, and food products in the humid
subtropical and tropical regions, and A. flavis is the
most common cause of food spoilage in the tropics.
Regions where aflatoxin intake is common also tend
to have high levels of HBV infection, making epidem-
iologic analysis difficult, but it appears that chronic
exposure to aflatoxin is carcinogenic. Chronic feeding
of aflatoxin B1, the most hepatotoxic of the aflatoxins,
induced liver cancer in many animal species. The
intake of aflatoxin B1 by inhabitants of 10 villages in
China was shown to correlate with HCC mortality
rates [60].
Higher HCC mortality rates have also been found
in people who drink pond-ditch water contaminated
with the blue-green algal toxin microcystin, the toxin
also causing hepatic hemorrhage and necrosis [60].
Other mycotoxins such as sterigmatocystin, produced
by Aspergillus, and luteoskyrin and cyclochlorotine,
metabolites of Penicillium islandicum found in spoilt rice
and grain, have been demonstrated to have carcino-
genic effects in experimental animals, but similar
effects have not been established in humans.
Chemical carcinogens
Variations in HCC incidence rates within a region may
also be explained by differences in levels of exposure to
chemical carcinogens. Improved living conditions can
result in the increased use of a wide variety of chemicals
in industry and in items such as processed foods,
cleaning reagents, cosmetics, and pharmaceuticals.
Other chemicals like nitrites, hydrocarbons, solvents,
organochlorine pesticides, primary metals, and poly-
chlorinated biphenyls have also been implicated as
potential carcinogens. Many of these are hepatotoxic
and have been shown experimentally to have car-
cinogenic potential. Sweden, a highly developed and
industrialized country, has a higher HCC rate than
other European nations. Chinese farmers from Qidong
province who drank ditch water contaminated with
pesticides such as DDT, which was once widely used,
were found to have a crude death rate from HCC
of 62–110 per 100 000 population, compared with
0–11.9 deaths per 100 000 among those who drank
well-water. The sinking of more wells in the country
resulted in a 20–30% reduction in the frequency of
liver cancer [61].
Radiation and Thorotrast
The victims of the Hiroshima and Nagasaki atomic
bombing did not show evidence of increased liver
cancer, although there is good evidence that internal a
and b radiation is carcinogenic. Thorotrast, colloidal
thorium dioxide, used as an angiographic agent in the
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1930s, emits high levels of a, b and g radiation with
a long physical and biological half-life. Thorotrast
accumulates in the macrophages of the reticuloendo-
thelial system, particularly the liver, and produces
hepatic fibrosis, angiosarcoma, cholangiocarcinoma,
and HCC. Angiosacoma was more commonly associ-
ated with Thorotrast in western countries while in
Japan, both cholangiocarcinoma and HCC were more
common. HCC developed at least 10 years after the
deposition of Thorotrast in the liver compared with
shorter intervals required for the other two tumors.
Miscellaneous factors
Malnutrition is common in many of the geographic
areas of high prevalence of HCC but the association is
more likely due to HBV infection and hepatotoxins
that are also prevalent in these areas. Existing infor-
mation suggests that over-nourishment is more likely
to promote neoplastic growth, as shown by the associ-
ation of a high intake of animal fat and cholesterol,
and obesity, with cancer of the breast, endometrium,
colon, and pancreas [62]. Prolonged parenteral nutri-
tion in infancy may be complicated by cholestasis,
liver fibrosis and cirrhosis, with rare cases of liver
cancer [63].
There is no evidence to link parasitic infections with
HCC, although the relationship between liver flukes
and cholangiocarcinoma is well recognized. It is pos-
sible that certain types of medication may expedite
hepatocarcinogenesis. Anecdotal case reports have
incriminated azathioprine, methotrexate, denazol,
tamoxifen, and cytoproterone acetate in this role.
There are also very rare reports of HCC developing in
various forms of chronic liver disease including auto-
immune chronic hepatitis and primary biliary cirrhosis.
Chronic alcohol abuse often complicates HCC,
especially in low-incidence areas where HBV infection
is uncommon. While alcohol has been incriminated in
the causation of carcinomas in the larynx, mouth, and
esophagus, it is not a cirrhosis-causing agent and has
not been shown to have a carcinogenic effect in the
liver. Alcohol may have a role as a co-carcinogen with
other agents such as HBV, HCV, hepatotoxins, and
tobacco. Alcohol may also have a role through its
induction of the microsomal cytochrome P450 system,
which is responsible for the metabolic activation and
inactivation of diverse chemical carcinogens including
aflatoxins. The cytochrome P450 system is also highly
inducible by smoking, which is a significant risk factor
for HCC, having also a synergistic effect with alcohol
and chronic HBV infection [64].
While a vast array of naturally occurring substances,
which can be found in drinking water, foodstuffs,
native and herbal remedies, have been suspected car-
cinogens; most have not been proven to be so. Among
these substances are the pyrrolizidine alkaloids found
in species of Senecio, Crotalaria and Heliotropium plants,
comfrey, which is used as a green vegetable, tea and
animal fodder, and cycads that contain the glycoside
cycasins have been shown to be hepatotoxic and can
produce liver tumors in many animals. Other sub-
stances like tannic acid in tea and coffee, and safrole in
oils used for medicines and flavoring, are carcinogenic
in rodents.
Precancerous changes and hepatocarcinogenesis
The concept of premalignant lesions of the liver and
cellular alterations preceding fully developed HCC has
been controversial. Recent refinements in imaging
allow the identification and resection of nodular lesions
of 51 cm diameter and liver transplantation occa-
sionally provides explanted liver tissues with early or
premalignant lesions for more exacting morphological
and molecular examination.
The diagnostic criteria for early HCC include
nuclear crowding, increased cytoplasmic basophilia,
and microacinar formation [65]. These criteria have
been successfully employed for evaluating ultrasound-
guided needle biopsies of nodular hepatic lesions [66].
Tumor size is another important criterion, as one study
involving 58 resected small nodular lesions revealed
every lesion exceeding 1.5 cm diameter to be an early
carcinoma [67]. However, the sizes of benign and early
malignant lesions may overlap and adenomas can ex-
ceed 2 cm in diameter. The liver cell populations that
precede the development of overt metastasizing HCC
are characterized by hyperplastic expansive collections
of hepatocytes, which may have clear, basophilic or
acidophilic cytoplasm or may show pleomorphism and
megalocytosis. The gradual loss of adult liver enzymes
and the appearance of fetal enzymes accompany these
features. Such changes are recognized as dysplastic
nodules (adenomatous hyperplasia) and liver cell
dysplasia.
Dysplastic nodule
The dysplastic nodule, also known as adenomatous
hyperplasia, hepatocellular pseudotumor, macroregen-
erative nodule, adenomatous regeneration, adeno-
matous hyperplastic nodule, and borderline nodule, is
defined as a nodule that is usually, but not always,
found in the setting of cirrhosis and is distinct from
the surrounding parenchyma in terms of size, color,
texture, and bulging cut surface [68]. These nodules
grow to a large size and appear tumor-like, ranging
from 1 to 15 cm, most measuring 2–3 cm. Such
nodules are readily detected by modern imaging tech-
niques and occur usually in individuals who are being
screened for HCC. They may occur in the presence
of established HCC and are often larger and more
numerous in this situation. The term “dysplastic
nodule” does not refer to a nodule made up of dys-
plastic hepatocytes of small or large cell type, in fact,
they often consist of normal-appearing hepatocytes
with only foci of cellular atypia within the nodules.
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They are not encapsulated but are often partially or
completely surrounded by a rim of fibrous tissue in the
manner of ordinary cirrhotic nodules. The nodules
have a bulging cut surface and show compression of
the surrounding liver parenchyma. Unlike focal
nodular hyperplasia, they do not show a central scar
and do not contain necrotic or hemorrhagic areas as in
HCC. Microscopically, they are composed of normal-
appearing hepatocytes arranged in plates of one or two
cells thickness with areas of fatty change. While there
may be some suggestion of a disordered growth
pattern, there may be no evidence of nuclear atypia.
The nodules are devoid of portal tracts [67].
Low-grade dysplastic nodules are defined by the
absence of cellular or architectural atypia, although
areas of large cell dysplasia may be present, making
distinction from ordinary regenerative nodules diffi-
cult. It has been suggested that an increased number
of arteries without corresponding bile ducts (so-called
“unpaired arteries”) is evidence of a dysplastic nodule
[69]. High-grade dysplastic nodules show focal or
diffuse cytologic or architectural atypia in the form of
diffuse small cell dysplasia or microacinar formation.
The areas of atypia appear as subnodules or nodule-in-
nodule, pushing against the surrounding hepatocytes
within the dysplastic nodule. These subnodules have
been shown to proliferate more rapidly than the sur-
rounding nodule and may be difficult to distinguish
from well-differentiated HCC. They may also display
iron resistance in an otherwise siderotic nodule, in-
creased copper, fatty change, Mallory’s hyaline, clear
cell change or thickened trabeculae.
In one study, about 50% of patients with biopsy-
proven dysplastic nodules developed carcinoma over
a 6–50-month period [70]. Cases have been described
in which carcinomas were clearly embedded within
adenomatous lesion, and in one report, an HBV-
related carcinoma within an adenomatous lesion was
shown to have an identical clonal HBV integration
pattern to the surrounding hepatocytes, indicating a
common origin [71]. There is also evidence that these
nodules are monoclonal in nature.
Nodular regenerative hyperplasia is a condition in
which the entire liver is interspersed with foci of hyper-
plastic hepatocytes consisting of plates of more than
one cell thickness in the periportal areas. In some in-
stances these regenerative nodules progress to multiple
adenomatous lesions of up to several centimeters in
diameter. It is suspected that nodular regenerative
hyperplasia may be a premalignant condition [72] and
indeed progression of this lesion to carcinoma has been
reported [73].
Liver cell dysplasia
Liver cell dysplasia refers to the presence of large
hepatocytes with bizarre, hyperchromatic and occa-
sionally multiple nuclei (large cell dysplasia). These
cells occur in groups and may sometimes occupy entire
cirrhotic nodules. One contention maintains that dys-
plastic hepatocytes represent a premalignant change,
but reports from South Africa and Japan have refuted
this, suggesting that liver cell dysplasia may be a
regenerative or hyperplastic phenomenon [74]. More
recent support for the premalignant concept comes
from ploidy studies, which indicate that morphologi-
cally dysplastic hepatocytes are associated with DNA
aneuploidy [75–77], although conflicting results have
also been reported [78].
Another form of liver dysplasia has been described in
which the cells have small nuclei and relatively less than
normal, often basophilic cytoplasm, yielding an in-
creased nuclear to cytoplasmic ratio. This has come to
be known as small cell dysplasia [79]. These cells also
show nuclear pleomorphism and sometimes multi-
nucleation, and have been readily identified in cases
from Asia associated with HCC. This association is
less so among North American and European
populations.
A recent study of various atypical features including
large and small cell dysplasia, cytoplasmic basophilia,
small microacinar structures, peripheral distribution
of nuclei, nuclear irregularities, and thickened liver
plates, found that when used separately, none were
useful to discriminate between cirrhosis without tumor
and cirrhosis associated with HCC. Acinar structures,
thickened liver trabeculae, peripheral distribution of
nuclei, and nuclear irregularities seemed to be the
most specific indicators of association with HCC,
and cirrhotic nodules showing four or more of the
assessed features were often located in the vicinity of a
tumor [80].
Carcinogenesis
It is accepted that neoplastic development is a stepwise
process that involves at least two or more genetic events
cumulating in unrestrained cell growth, tissue invasion,
and metastasis. These genetic changes may be inherited
as germline mutations, which predispose to an in-
creased risk for the development of cancer. More often
they are acquired and the result of any one or a
combination of chemical, physical or biological insults
to the cell [81]. An alternative view is that neoplastic
development results from adaptive responses to
environmental perturbations [82].
Colonic carcinogenesis is the best-characterized
human cancer model. The so-called adenoma-
carcinoma sequence in the colon formed the basis for
studying the underlying molecular events and the re-
sponsible genes. While some animal models of hepatic
carcinogenesis satisfy such a sequence of events, the
situation in human HCC is not as well defined.
HCCs display numerous genetic abnormalities
including chromosomal deletions, re-arrangements,
aneuploidy, gene amplifications, and mutations, as well
as epigenetic alterations including modulation of DNA
methylation. Such genetic and epigenetic alterations
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combine to activate positive mediators of cell prolif-
eration and inactivate negative mediators of cell pro-
liferation including tumor suppressor genes, resulting
in autonomous growth properties. Because HCCs
exhibit a high degree of genetic heterogeneity it is likely
that multiple molecular pathways may be involved in
the production of subsets of hepatocellular tumors.
HCC has revealed allele losses from chromosomes
4, 5q, 11p, 13q, 16q, and 17p (especially the latter).
Mutations of p53 have been documented in
HCC-derived cell lines and in as many as 80% of liver
cancers in China and southern Africa [83,84]. These
mutations have commonly consisted of a transversion
of G to T to C at the third base of codon 249. While
p53 mutations may have an important role in hepato-
carcinogenesis, such mutations represent one of the
most commonly recognized changes in human carci-
nomas and are generally a late event in carcinogenesis.
Aflatoxin B1 causes transversion of G to T almost
exclusively and preferentially binds to G residues in
the GC-rich regions in codon 249 of the p53 gene,
suggesting that this mycotoxin may have a carcinogenic
role in a subset of patients with HCC.
Changes in DNA methylation have been proposed
to be an essential step in carcinogenesis as they relate
to the regulation of gene expression and cellular
differentiation. DNA hypomethylation has been
reported in chemical hepatocarcinogenesis [85] but
increases in deoxycytosine methylation have been
reported following ingestion of the carcinogen metha-
pyriline [86]. Prolonged feeding of diets deficient
in sources of transferable methyl groups such as
Figure 2. Proposed sequence of hepatocarcinogenesis (after Chan et al. [89]).
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choline and methionine induced a high incidence of
HCC in rats [87].
The relationship between cirrhosis and HCC is well
accepted but the reason is largely unknown. It has been
suggested that a deficiency in the ability to repair O(6)-
methylguanine DNA underlies this increased risk,
although this may be only one of several contributory
factors [88]. A proposed sequence of hepatocarcino-
genesis is shown in Figure 2 [89].
Alcohol cannot be considered as a bona fide
promoting agent for HCC and appears to act through
its induction of cirrhosis as well as the modulation,
in an as yet ill-defined manner, of the process of
carcinogenesis with other recognized carcinogenic
agents such as HBV and HCV [90]. The association of
HBV and HCC is strong and in addition to the sup-
porting arguments made earlier, hepatoma cell lines
have successfully produced HBV surface antigen
(HBsAg) and have been demonstrated to have inte-
grated HBV DNA. HBV DNA integration is almost
invariably present in HBsAg-positive HCCs. The pres-
ence of such integration in the non-tumorous hepato-
cytes of these livers further indicates that integration
precedes carcinogenesis; however, no oncogenes have
yet been identified within the HBV genome. While the
virus is frequently fragmented after it integrates into
the hepatocyte genome, the HBx gene appears to be
consistently retained in a functional form, leading to
speculation of its role in carcinogenesis. In tissue
cultures, the X protein acts as a transcriptional trans-
activator of viral genes and it is possible that this
protein may alter host gene expression in a manner that
leads to HCC formation. Transgenic mice harboring
the HBx gene develop multifocal areas of altered
hepatocytes, benign adenomas, and eventually HCC
[91]. Studies in HBx transgenic mice indicate that
the HBx gene has mitogenic activity both in vitro and
in vivo and suggest that the HBx gene contributes to
hepatocarcinogenesis by driving cells into deregulated
cell cycle control [92].
Finally, a causal association between HBV and HCC
is supported by numerous studies of three hepadna-
viruses, which are phylogenetically related to the
human HBV. These occur in the eastern woodchuck
(Marmota manax), Beechey ground squirrel (Spermo-
philus beecheyi), and Peking duck (Anas domesticus), in
which persistent antigenemia is associated with the
development of HCC [93].
Much important information has been accumulated
on the molecular and genetic events leading up to
HCC, especially in the experimental model, but the
genes involved and the mutations necessary for hepa-
tocarcinogenesis still remain largely unknown [94].
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